CDKN1B and head and neck cancer: The miR‐196a in EVs derived from cancer‐associated fibroblasts (CAFs) promotes proliferation and resistance to cisplatin in head and neck cancer cells by targeting the tumor suppressors cyclin‐dependent kinase inhibitor 1B (CDKN1B) and inhibitor of growth protein 5 (ING5).60